Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Intangibles (2020 - 2025)

Historic Intangibles for Northwest Biotherapeutics (NWBO) over the last 6 years, with Q3 2025 value amounting to $1.3 million.

  • Northwest Biotherapeutics' Intangibles changed 0.0% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $1.3 million for FY2024, which is 0.0% changed from last year.
  • Latest data reveals that Northwest Biotherapeutics reported Intangibles of $1.3 million as of Q3 2025, which was down 0.0% from $1.3 million recorded in Q2 2025.
  • Northwest Biotherapeutics' 5-year Intangibles high stood at $1.3 million for Q1 2021, and its period low was $1.3 million during Q1 2021.
  • Over the past 5 years, Northwest Biotherapeutics' median Intangibles value was $1.3 million (recorded in 2021), while the average stood at $1.3 million.
  • Over the last 5 years, Northwest Biotherapeutics' Intangibles had its largest YoY gain of 0.0% in 2021, and its largest YoY loss of 0.0% in 2021.
  • Northwest Biotherapeutics' Intangibles (Quarter) stood at $1.3 million in 2021, then changed by 0.0% to $1.3 million in 2022, then changed by 0.0% to $1.3 million in 2023, then changed by 0.0% to $1.3 million in 2024, then changed by 0.0% to $1.3 million in 2025.
  • Its Intangibles was $1.3 million in Q3 2025, compared to $1.3 million in Q2 2025 and $1.3 million in Q1 2025.